Authors
Loading...
Quantitative analysis reveals cash flow, liquidity, and leverage do not individually impact financial distress in listed pharmaceutical companies, suggesting further investigation is needed.
Manangkabo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: